SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways

Abstract Background The SUMO-activating enzyme SAE1 is indispensable for protein SUMOylation. A dysregulation of SAE1 expression involves in progression of several human cancers. However, its biological roles of SAE1 in glioma are unclear by now. Methods The differential proteome between human gliom...

Full description

Bibliographic Details
Main Authors: Yanfang Yang, Ziwei Liang, Zijing Xia, Xixi Wang, Yanni Ma, Zenghua Sheng, Qingjia Gu, Guobo Shen, Liangxue Zhou, Hongxia Zhu, Ningzhi Xu, Shufang Liang
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Cell Communication and Signaling
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12964-019-0392-9
_version_ 1819144775916322816
author Yanfang Yang
Ziwei Liang
Zijing Xia
Xixi Wang
Yanni Ma
Zenghua Sheng
Qingjia Gu
Guobo Shen
Liangxue Zhou
Hongxia Zhu
Ningzhi Xu
Shufang Liang
author_facet Yanfang Yang
Ziwei Liang
Zijing Xia
Xixi Wang
Yanni Ma
Zenghua Sheng
Qingjia Gu
Guobo Shen
Liangxue Zhou
Hongxia Zhu
Ningzhi Xu
Shufang Liang
author_sort Yanfang Yang
collection DOAJ
description Abstract Background The SUMO-activating enzyme SAE1 is indispensable for protein SUMOylation. A dysregulation of SAE1 expression involves in progression of several human cancers. However, its biological roles of SAE1 in glioma are unclear by now. Methods The differential proteome between human glioma tissues and para-cancerous brain tissues were identified by LC-MS/MS. SAE1 expression was further assessed by immunohistochemistry. The patient overall survival versus SAE1 expression level was evaluated by Kaplan–Meier method. The glioma cell growth and migration were evaluated under SAE1 overexpression or inhibition by the CCK8, transwell assay and wound healing analysis. The SUMO1 modified target proteins were enriched from total cellular or tissue proteins by incubation with the anti-SUMO1 antibody on protein-A beads overnight, then the SUMOylated proteins were detected by Western blot. Cell apoptosis and cell cycle were analyzed by flow cytometry. The nude mouse xenograft was determined glioma growth and tumorigenicity in vivo. Results SAE1 is identified to increase in glioma tissues by a quantitative proteomic dissection, and SAE1 upregulation indicates a high level of tumor malignancy grade and a poor overall survival for glioma patients. SAE1 overexpression induces an increase of the SUMOylation and Ser473 phosphorylation of AKT, which promotes glioma cell growth in vitro and in nude mouse tumor model. On the contrary, SAE1 silence induces an obvious suppression of the SUMOylation and Ser473 phosphorylation of Akt, which inhibits glioma cell proliferation and the tumor xenograft growth through inducing cell cycle arrest at G2 phase and cell apoptosis driven by serial biochemical molecular events. Conclusion SAE1 promotes glioma cancer progression via enhancing Akt SUMOylation-mediated signaling pathway, which indicates targeting SUMOylation is a promising therapeutic strategy for human glioma.
first_indexed 2024-12-22T12:47:30Z
format Article
id doaj.art-5af56e3dc71949718dc1c5b58fae6876
institution Directory Open Access Journal
issn 1478-811X
language English
last_indexed 2024-12-22T12:47:30Z
publishDate 2019-07-01
publisher BMC
record_format Article
series Cell Communication and Signaling
spelling doaj.art-5af56e3dc71949718dc1c5b58fae68762022-12-21T18:25:16ZengBMCCell Communication and Signaling1478-811X2019-07-0117111410.1186/s12964-019-0392-9SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathwaysYanfang Yang0Ziwei Liang1Zijing Xia2Xixi Wang3Yanni Ma4Zenghua Sheng5Qingjia Gu6Guobo Shen7Liangxue Zhou8Hongxia Zhu9Ningzhi Xu10Shufang Liang11State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyDepartment of Rheumatology and Immunology, West China Hospital, Sichuan UniversityState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyDepartment of Otorhinolaryngology, University of Electronic Science and Technology of China, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s HospitalState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, Cancer Institute & Cancer Hospital, Chinese Academy of Medical SciencesState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for BiotherapyAbstract Background The SUMO-activating enzyme SAE1 is indispensable for protein SUMOylation. A dysregulation of SAE1 expression involves in progression of several human cancers. However, its biological roles of SAE1 in glioma are unclear by now. Methods The differential proteome between human glioma tissues and para-cancerous brain tissues were identified by LC-MS/MS. SAE1 expression was further assessed by immunohistochemistry. The patient overall survival versus SAE1 expression level was evaluated by Kaplan–Meier method. The glioma cell growth and migration were evaluated under SAE1 overexpression or inhibition by the CCK8, transwell assay and wound healing analysis. The SUMO1 modified target proteins were enriched from total cellular or tissue proteins by incubation with the anti-SUMO1 antibody on protein-A beads overnight, then the SUMOylated proteins were detected by Western blot. Cell apoptosis and cell cycle were analyzed by flow cytometry. The nude mouse xenograft was determined glioma growth and tumorigenicity in vivo. Results SAE1 is identified to increase in glioma tissues by a quantitative proteomic dissection, and SAE1 upregulation indicates a high level of tumor malignancy grade and a poor overall survival for glioma patients. SAE1 overexpression induces an increase of the SUMOylation and Ser473 phosphorylation of AKT, which promotes glioma cell growth in vitro and in nude mouse tumor model. On the contrary, SAE1 silence induces an obvious suppression of the SUMOylation and Ser473 phosphorylation of Akt, which inhibits glioma cell proliferation and the tumor xenograft growth through inducing cell cycle arrest at G2 phase and cell apoptosis driven by serial biochemical molecular events. Conclusion SAE1 promotes glioma cancer progression via enhancing Akt SUMOylation-mediated signaling pathway, which indicates targeting SUMOylation is a promising therapeutic strategy for human glioma.http://link.springer.com/article/10.1186/s12964-019-0392-9GliomaSAE1SUMOylationPhosphorylationAkt signaling pathway
spellingShingle Yanfang Yang
Ziwei Liang
Zijing Xia
Xixi Wang
Yanni Ma
Zenghua Sheng
Qingjia Gu
Guobo Shen
Liangxue Zhou
Hongxia Zhu
Ningzhi Xu
Shufang Liang
SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways
Cell Communication and Signaling
Glioma
SAE1
SUMOylation
Phosphorylation
Akt signaling pathway
title SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways
title_full SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways
title_fullStr SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways
title_full_unstemmed SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways
title_short SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways
title_sort sae1 promotes human glioma progression through activating akt sumoylation mediated signaling pathways
topic Glioma
SAE1
SUMOylation
Phosphorylation
Akt signaling pathway
url http://link.springer.com/article/10.1186/s12964-019-0392-9
work_keys_str_mv AT yanfangyang sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT ziweiliang sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT zijingxia sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT xixiwang sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT yannima sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT zenghuasheng sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT qingjiagu sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT guoboshen sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT liangxuezhou sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT hongxiazhu sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT ningzhixu sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways
AT shufangliang sae1promoteshumangliomaprogressionthroughactivatingaktsumoylationmediatedsignalingpathways